AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TARS · NASDAQ · Biotechnology

Tarsus Pharmaceuticals (TARS)

Commercializes XDEMVY for Demodex blepharitis and develops additional eye-care and infectious-disease therapies.

$75.88

vs last close−1.20 (−1.56%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	2	13	28	41	48	66	78	103	119	152	162	174
Cost of revenue	0	1	2	3	3	5	5	6	25	11	9	12
Gross profit	1	12	26	38	45	61	73	96	94	141	153	162
	42	56	64	71	70	86	99	119	109	149	159	182
Research & development	12	13	12	12	12	17	14	16	16	18	22	31
	30	43	52	59	58	69	85	103	109	131	136	151
General & administrative	30	0	0	0	0	0	0	0	0	0	0	151
Other expenses	0	0	0	0	0	0	0	0	−16	0	0	0
Operating income	−41	−44	−38	−33	−25	−24	−26	−22	−15	−8	−6	−20
	2	3	2	0	2	1	1	2	2	2	−3	4
Interest income	3	3	3	4	4	4	3	4	4	4	4	4
Interest expense	1	1	1	2	2	2	2	2	2	2	2	2
Other non-operating income	−3	−4	−3	−2	−4	−4	−3	−4	−2	−4	1	−6
Income before tax	−39	−42	−36	−33	−23	−23	−25	−20	−13	−6	−9	−16
Income tax expense	0	0	0	0	0	0	0	0	0	2	−2	3
Net income from continuing operations	−39	−42	−36	−33	−23	−23	−25	−20	−13	−8	−7	−19
Net income	−39	−42	−36	−33	−23	−23	−25	−20	−13	−8	−7	−19
EPS, basic	−$1.28	−$1.31	−$1.01	−$0.88	−$0.61	−$0.60	−$0.64	−$0.48	−$0.30	−$0.20	−$0.16	−$0.43
EPS, diluted	−$1.28	−$1.31	−$1.01	−$0.88	−$0.61	−$0.60	−$0.64	−$0.48	−$0.30	−$0.20	−$0.16	−$0.43
Weighted average shares, basic	31	32	35	38	38	39	39	42	43	43	43	43
Weighted average shares, diluted	31	32	35	38	38	39	39	42	43	43	43	43
EBITDA	−38	−41	−34	−31	−21	−20	−22	−18	−12	−4	−7	−13
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	1
EBIT	−38	−41	−35	−31	−21	−21	−23	−18	−13	−4	−7	−14